Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France

Sponsor
Bristol-Myers Squibb
Study ID
NCT06735781
Status
Completed

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    As prescribed by the treating clinician

Study Details

The purpose of this study is to evaluate real-world effectiveness of neoadjuvant nivolumab plus chemotherapy in France.

Key Dates

Start date
Sep 5, 2024
Status verified
Dec 2024
Primary completion
Oct 1, 2024
Completion
Oct 1, 2024

Study Design

Enrollment
101 participants (actual)

Arms

  • Arm: Neoadjuvant nivolumab plus chemotherapy treatment

Primary Outcome Measure

Rate of pathological complete response on date of surgery [ Time Frame: Up to 31 months (until loss of follow-up, death, or end of study observation period) ]

Related Studies